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Abstract: Children receiving radiotherapy face the probability of a subsequent malignant
neoplasm (SMN). In some cases, the predicted SMN risk can be reduced by proton therapy.
The purpose of this study was to apply the most comprehensive dose assessment methods
to estimate the reduction in SMN risk after proton therapy vs. photon therapy for a
13-year-old girl requiring craniospinal irradiation (CSI). We reconstructed the equivalent
dose throughout the patient’s body from therapeutic and stray radiation and applied SMN
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incidence and mortality risk models for each modality. Excluding skin cancer, the risk
of incidence after proton CSI was a third of that of photon CSI. The predicted absolute
SMN risks were high. For photon CSI, the SMN incidence rates greater than 10% were for
thyroid, non-melanoma skin, lung, colon, stomach, and other solid cancers, and for proton
CSI they were non-melanoma skin, lung, and other solid cancers. In each setting, lung
cancer accounted for half the risk of mortality. In conclusion, the predicted SMN risk for a
13-year-old girl undergoing proton CSI was reduced vs. photon CSI. This study demonstrates
the feasibility of inter-institutional whole-body dose and risk assessments and also serves as
a model for including risk estimation in personalized cancer care.
Keywords: pediatric medulloblastoma; second malignant neoplasm risk; craniospinal
irradiation; health care disparities; proton therapy

1. Introduction
In 2012, approximately 163,000 children aged 14 and younger were diagnosed with cancer
worldwide [1], about half of whom received radiotherapy. Eighty percent of these children lived in
developing countries [2] that do not offer advanced radiotherapy techniques, such as proton therapy,
that are capable of reducing the dose in non-tumor tissues vs. traditional radiation therapies [3,4].
The 5-year survival rate for children with cancer is high—83% in the U.S. [5] and lower but improving
in developing countries [2]. However, whether treated in developed or developing countries, childhood
cancer survivors face the likelihood of long-term effects from their treatment that can be debilitating,
chronic, and even fatal. Children receiving radiotherapy are particularly vulnerable compared to adults
because they have a higher sensitivity to many of these radiation effects, their organs are closer to
the treatment fields, and they have longer expected survival times. The late effect of greatest concern
for children who receive radiotherapy is the development of a treatment-related subsequent malignant
neoplasm (SMN) [6]. The use of proton radiotherapy for treating children with curable solid tumors to
reduce the risk of late effects such as SMN is expanding rapidly in North America, Europe, and Asia [7]
but is not currently available in South America, Africa, and Australia, including the regions of Central
America, Southeast Asia, and the Middle East [8].
By applying risk models and accurate dosimetry, the lifetime risks of SMN can be estimated for
individuals and populations that were exposed to radiation. Some studies have estimated the risk of
SMN for children receiving radiotherapy for tumors of the central nervous system [9–14], the second
most common site of childhood cancer worldwide. These studies estimated the radiation dose in organs
and tissues from therapeutic radiation within the treatment fields and from leakage and scatter radiation
outside the fields. Some studies have compared proton vs. photon therapy within a single institution in
terms of the predicted risk of secondary effects [11,12,14–19], each of which found proton therapy to
be superior to photon therapy, with fewer radiotherapy-related toxicities and equal tumor control [20].
Over the past 12 years, the methods of evaluating the radiation dose throughout the patients’ bodies have
evolved, and now a comprehensive estimate of SMN risk based on these advanced dosimetric methods
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is achievable, and this can be done inter-institutionally. Until now, a comparison in SMN risks had
not been made between two institutions, one having proton therapy and the other having only photon
therapy, for a child receiving radiotherapy for brain cancer. Such studies are needed to generate evidence
to inform treatment decisions and planning in regions in which proton therapy is not locally available.
For these reasons, using the most advanced and comprehensive dose reconstruction methods to estimate
SMN risks, we compared a best-available radiotherapy in an academic cancer center in the Middle East
(photon therapy) with that available in an academic cancer center in the U.S. (proton therapy) to treat a
pediatric brain cancer.
The purpose of this study was to estimate for a single patient the reduction in SMN risk that may be
achieved by applying proton beams rather than photon beams in craniospinal irradiation (CSI). We did
this by estimating the predicted risks of radiogenic SMN incidence and mortality for a 13-year-old girl
in two separate clinical environments. These estimates included dosimetric contributions from both
therapeutic and stray radiation calculated in this study and widely-accepted SMN risk models from the
literature. As a result, we were able to determine the SMN sites of greatest concern for each modality.
In addition, in this multi-institutional study, we expanded, tested, and improved our methods for
estimating out-of-field dose in photon radiotherapy, which will be applied in future studies.
2. Methods and Materials
2.1. Patient and Treatment Objectives
To test a typical scenario for a pediatric cancer patient with prospects for long-term survival of
a primary cancer, we created separate CSI treatments for a patient diagnosed with medulloblastoma
according to the standards of care of two leading academic cancer treatment facilities in their respective
regions—The University of Texas MD Anderson Cancer Center (“MD Anderson”) using protons [21]
and the American University of Beirut Medical Center (AUBMC) using photons. Unlike MD Anderson,
AUBMC offers only photon therapy and not proton therapy, a limitation that is true of cancer care
facilities throughout the Middle East and all developing countries (China and South Africa are the
only countries classified as developing by the World Bank in which patients have been treated with
proton therapy, but they have accumulated less than 2,000 patients treated to date) [8,22]. The intent
of the CSI was to sterilize potential residual cancer cells in the tumor bed, central nervous system, and
cerebrospinal fluid by delivering the prescribed dose, DRx , of 23.4 Gy-RBE to the entire craniospinal axis
(1.8 Gy-RBE/fraction in 13 fractions). The patient was a 13-year-old girl, with a height of 147 cm and a
mass of 42.6 kg, who had been treated with proton CSI at MD Anderson. As part of the patient’s care,
computed tomography (CT) images in the supine position had been acquired for treatment planning
purposes; the images extended from the patient’s mid-thigh to beyond the top of the head (71.5 cm),
with a reconstructed slice thickness of 2.5 mm (pixel size 0.98 mm × 0.98 mm). Target and avoidance
structures were contoured as well as organs and tissues that corresponded to possible SMN sites, which
included the “whole body” (i.e., that captured in the CT image set), bladder, breasts, colon, liver, lungs,
ovaries, skin, stomach, thyroid, uterus, rectum, red bone marrow, and a “remainder” that was created
as a Boolean subtraction of the union of all specific SMN-site organs and tissues from the whole body.
This remainder volume included the central nervous system. SMN risks from intracranial boost fields
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targeting the tumor resection bed or posterior fossa were not considered in this study because boost
fields are small and bear much less importance for SMN risk than the CSI fields [10]. This study was
performed under protocols approved by MD Anderson’s and AUBMC’s institutional review boards.
2.1.1. Proton CSI
The MD Anderson standard proton treatment technique for pediatric CSI is administered with the
patient positioned in the supine position [21]. The RBE of therapeutic protons for deterministic effects
throughout the treatment volume was taken as 1.1 (ICRU 2007). Therefore, the absorbed dose from
proton beams that corresponded to DRx was 21.3 Gy. A treatment couch model had been added to
the CT images to account for attenuation through the couch. The proton CSI treatment plan was created
using a commercial treatment planning system (TPS; Eclipse, version 8.9; Varian Medical Systems, Inc.,
Palo Alto, CA, USA) [23]. The treatment unit was MD Anderson’s passive scattering proton therapy
gantry (Probeat, Hitachi America, Ltd., Brisbane, CA, USA) that was described previously, along with
the CSI delivery technique [9,23–25]. The proton CSI plan comprised five treatment fields: lower,
middle, and upper posterior anterior spinal fields (LPA, MPA, and UPA) and right and left posterior
oblique cranial fields (RPO and LPO). The original plan included two longitudinal shifts of the position
of the abutment of the fields, but these shifts were not taken into consideration in this research study.
The field characteristics are listed in Table 1.
Table 1. Treatment field characteristics for the proton CSI, with Monitor Units listed for DRx .
“Air gap” refers to the distance between the distal edge of most downstream component of
the treatment unit (range compensator) and the proximal surface of the patient along the
central beam axis.
Proton CSI

LPA

MPA

UPA

RPO

LPO

Monitor Units
Nominal injection beam energy (MeV)
Range in patient (cm H2 O)
Nominal SOBP width (cm)
Gantry angle (◦ )
Couch rotation angle (◦ )
Air gap (cm)
Aperture block thickness (cm)
Pre-collimated field size (cm × cm)
Collimated field, major axis (cm)
Collimated field, minor axis (cm)

2493
180
14.2
7
180
0
23
6
25 × 25
22.7
6.1

2594
160
10.9
6
180
0
25
4
25 × 25
13.4
4.8

2577
160
11.4
5
180
0
26
4
25 × 25
11.9
5.5

1349
200
15.3
16
255
2
38
6
25 × 25
21.1
16.7

1323
200
15.8
16
105
358
39
6
25 × 25
20.7
16.9

Abbreviations: LPA = lower posterior anterior; MPA = middle posterior anterior; UPA = upper posterior anterior;
RPO = right posterior oblique; LPO = left posterior oblique; SOBP = spread-out Bragg peak.

The TPS was used to calculate the in-field dose throughout the virtual geometry, including the patient
and the treatment couch, with a treatment planning calculation grid of 2.5 mm. Equivalent dose from
secondary neutrons was calculated in each voxel using the Monte Carlo Proton Radiotherapy Treatment
Planning (MCPRTP) system [9,23,26,27]. The MCPRTP system was modified prior to this study to
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include a lattice tally instead of a mesh tally to calculate dose within the patient [28], an upgrade
of the dose engine to version 2.7c of the Monte Carlo N-Particle eXtended code [29], more-specific
isotopic materials cards that call cross-section tables when available, the most up-to-date data libraries,
an improved multiple Coulomb scattering algorithm [30,31], a reduced bin size for more precise proton
stopping power, and removal of triton and 3 He tracking. The system was validated by comparing its
results to the results of previous studies and measured data. These changes resulted in more accurate
dosimetric calculations, faster simulation times, and reduced variance. The treatment-plan Digital
Imaging and Communications in Medicine-Radiation Therapy (DICOM-RT) objects [32]—RT Image,
RT Plan, RT Dose, and RT Structure Set—were exported to separate files and imported into MCPRTP
to determine the secondary neutron absorbed dose. The geometric model included field-specific
components of the treatment unit, including the structural and shielding materials, range modulator
wheel, scattering foil, range shifter, collimating aperture, and range compensator [25,26], and the extent
of the patient geometry in the planning CT image set. The CT number in each voxel was converted to a
mass density and a material composition in the geometric model using the machine-specific calibration
curve of the TPS [9,27].
2.1.2. Photon CSI
The RT Image and RT Structure Set files from MD Anderson containing the containing the
CT images and contoured volumes were de-identified [33,34], sent to AUBMC via encrypted and
password-protected data transfer, and imported into the AUBMC TPS (Panther, version 4.72, Prowess
Inc., Concord, CA, USA). Three-dimensional radiation therapy treatment fields were planned according
to the standard of care for pediatric photon CSI at AUBMC. The photon CSI plan comprised four 6-MV
treatment fields: LPA and UPA spinal fields and right and left lateral cranial fields (RL and LL) to be
delivered using AUBMC’s clinical linear accelerator and multi-leaf collimator (Artiste, Siemens Medical
Solutions USA, Inc., Malvern, PA, USA). Cranial and upper spinal fields were matched by rotating the
collimator used in the cranial fields, and no couch rotation was applied. Calculation points were placed
on the central axis of each field: at the midline for the brain field and at the anterior cord depth for each
spinal field. The fields were planned to deliver 23.4 Gy to calculation points while keeping the dose at
any point in the cord or brain below 115% of the dose at the calculation points. The RBE of photons
was taken as 1, so this prescription corresponded to a DRx of 23.4 Gy-RBE in common with the proton
plan. At AUBMC, photon CSI is performed typically with a patient in the prone position, with the chin
rotated out of the path of the upper spinal field. Because the CT image set had been collected at MD
Anderson with the patient in the supine position, adjustments were made in the photon plan to remove
the treatment couch and the patient’s chin from the TPS calculations to resemble the scenario in which
the CT image set had been collected with the patient in the prone position. Field characteristics are listed
in Table 2.
2.2. In-Field Equivalent Dose in Organs and Tissues
Mean organ doses were determined from voxelized dose distributions calculated by each TPS.
The absorbed dose in each voxel from primary fields, Dv (pri), in Gy was calculated throughout the
extent of the CT image set. The equivalent dose in each voxel from primary fields, Hv (pri), in Sv was
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the product of the mean radiation weighting factor, wR , used for deterministic and stochastic effects and
Dv (pri), or:
(1)
Hv (pri) = wR · Dv (pri)
wR was taken as 1 for primary photon fields, following the recommendation in International Commission
on Radiological Protection (ICRP) Publication 92 [35]. For primary proton fields, wR was estimated
as the mean quality factor [36,37] at any point within the fields, or approximately 1.1. HT (pri) was
calculated as the mass-weighted average of the equivalent dose in all voxels from primary fields within
a particular organ or tissue, T, using the following equation:
P
Hv ρv
v in T
(2)
HT = P
ρv
v in T

where ρv was the mass density of the tissue within a voxel. Finally, because the captured CT image
set did not extend from the thighs to the feet, the low-dose regions inferior to the CT image set were
not included in the red bone marrow, skin, remainder, and whole body volumes. To account for the
effect of the lessening of HT (pri) values by the weights of missing voxels in these regions, mean doses
for these volumes were reduced by multiplying them by the ratio of the mass of the patient in the CT
image set to the mass of the patient’s entire body recorded in her clinical chart, or 0.726. Effectively, this
approximation assumed that the dose in tissues inferior to the CT image set was negligible compared to
the dose within the CT image set.
Table 2. Treatment field characteristics for the photon CSI, with Monitor Units listed
for DRx .
Photon CSI

LPA

UPA

RL

LL

Monitor Units
Gantry angle (◦ )
Collimator angle (◦ )
X1 jaw (cm)
X2 jaw (cm)
Y1 jaw (cm)
Y2 jaw (cm)
Depth of calculation point (cm H2 O)
Effective square (cm)
Source-to-skin distance (cm)

3008
180
0
−4.4
3.7
−4.1
10.0
6.7
8.5
100

2785
180
0
−2.9
2.6
−9.0
19.0
5.1
7.4
100

1245
270
11
−9.3
10.9
−10.0
10.5
7.6
17.3
92.9

1268
90
349
−10.9
9.3
−10.0
10.5
8.1
17.3
92.7

Abbreviations: LPA = lower posterior anterior; UPA = upper posterior anterior; RL = right lateral;
LL = left lateral.

2.3. Stray Radiation Equivalent Dose in Organs and Tissues from Proton CSI
For proton CSI, absorbed dose from secondary neutrons in each voxel, Dv (n), was calculated
throughout the patient’s body—both in-field and out-of-field—using the MCPRTP system. The neutron
component of the in-field absorbed dose was calculated separately because of the higher wR for neutrons
than for protons. In proton beam radiotherapy, neutrons are produced in both the patient (“internal”
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neutrons) and treatment unit (“external neutrons”). In the MCPRTP system, Dv (n) was calculated for
external neutrons, Dv (next ), and internal neutrons, Dv (nint ), in separate simulations for each treatment
field, and the values were then summed for all fields. The values for wR were taken from the literature
based on Monte Carlo simulations of children that most closely approximated the size of the 13-year-old
girl in this study. The wR for external neutrons, wR,ext , was estimated as the mid-range value from a
previous study in which the wR values were calculated by the MCPRTP system for passive-scattering
proton CSI for a 10-year-old girl [10], so that wR,ext = 9.2. The wR for internal neutrons, wR,int , was
estimated as the average value from a previous study in which the wR values were calculated by MCPRTP
system for neutrons produced within a small, adult-male phantom for passive-scattering proton CSI [14],
so that wR,int = 9.0. Those previous studies defined wR according to the recommendation found in ICRP
Publication 92 [35]. Equation (1) was used to calculate Hv (next ) and Hv (nint ), Equation (2) was used to
calculate HT (next ) and HT (nint ), and these values were reduced as described in Section 2.2 for organs and
tissues that extended beyond the CT image set. Finally, for each treatment field, the total organ equivalent
dose from secondary neutrons, HT (n), was the sum of the external and internal neutron contributions, or:
HT (n) = HT (next ) + HT (nint )

(3)

The equivalent dose results for neutrons calculated by MCPRTP were reported per source particle,
Hv /sp in (Sv· sp− 1 ). Therefore, it was necessary to normalize the secondary neutron HT values to
the therapeutic dose in the following manner. A beam normalization volume (BNV) was contoured
for each field encompassing voxels in the central region of the proton CSI target volume of each field
and receiving approximately uniform absorbed dose. Additional separate MCPRTP simulations were
performed in which Dv (pri)/sp (in Gy· sp− 1 ) was determined and carried through the methods above
to calculate Hv (pri)/sp and H BNV (pri)/sp. Finally, HT was calculated as the product of HT /sp and the
number of source particles required for H BNV (pri)/sp from MCPRTP to match the H BNV (pri) from the
TPS, or:
{HBNV (pri)}TPS
HT
HT
o
× source particles =
×n
(4)
HT =
HBNV (pri)
sp
sp
sp

MCPRTP

2.4. Equivalent Dose in Organs and Tissues for Photon CSI
Dose calculation algorithms of TPSs for photon radiotherapy are accurate in the in-field region but
inaccurate in the out-of-field region [38–41]. To determine out-of-field equivalent dose in organs and
tissues that are sensitive to radiation carcinogenesis, we used three distinct approaches and compared
the results: (1) based on TPS calculations only; (2) a volume-weighted average based on measurements
in an anthropomorphic phantom; and (3) based on a an analytical model relating out-of-field dose to
distance from the CSI field edge.
2.4.1. Approach 1: TPS Calculations
In the first approach, we calculated the mean equivalent dose in organs and tissues for in-field,
partially in-field, and out-of-field organs based only on the TPS calculation. To maintain consistency
between the methods of calculating mean HT values, we exported the dose distribution calculated by the
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AUBMC TPS to DICOM RT Dose files, imported them into the MD Anderson TPS, and used the MD
Anderson TPS to calculate HT , as described in Section 2.2.
2.4.2. Approach 2: Volume-Weighted Average
In the second approach, we applied the volume-weighted averaging technique developed by
Howell et al. [42]. Dose volume histogram (DVH) data were exported from the TPS. For organs and
tissues that were entirely within the treatment field, the DVH data alone was used to determine the
equivalent dose in organs and tissues, as described in Section 2.2. For organs that were entirely outside
of the treatment field, the mean organ equivalent dose values were determined from our previous study
in which thermoluminescent dosimeter (TLD) measurements were made within an anthropomorphic
phantom receiving photon CSI at AUBMC [41]. The mean organ equivalent dose in each out-of-field
organ was calculated as an average of the equivalent doses of all TLD measurements within the organ.
For organs and tissues that were partially in the treatment field, as described by Howell et al., a sensitivity
analysis was performed to determine if the DVH data were sufficiently accurate for calculating the mean
organ dose. Specifically, if adjusting Dv in the voxels outside the 5% isodose surface by ±60% resulted in
a greater than ±5% difference in HT , then HT for that organ was estimated based on a volume-weighted
average that combined the TPS estimate of the in-field component of dose with a measured out-of-field
component of dose. If not, HT for that organ was determined based on the Dv values from the TPS.
2.4.3. Approach 3: Model-Based Estimate
In the third approach, we applied an analytical model developed in our previous study [41] of absorbed
dose vs. distance from the CSI field edge (i.e., 50% isodose surface). Because the treatment unit for this
study was the same as that in the previous study, the model and its fitted parameters were applied directly.
For each voxel that was more than 1 cm outside of the field edge, the Dv values were replaced by those
calculated by the following equation:
#
"


(r− µ1 )2
(r− µ2 )2
−
−
α
Dv
1 Gy
α1
2
2
2
2σ1
2σ2
+p
(5)
· p
e
e
= wR · DRx ·
Hv = wR · DRx ·
DRx v,model
100 cGy
2πσ12
2πσ22
where α1 = 224.8 cm-cGy/Gy, µ1 = −2.16 cm, σ1 = 1.57 cm, α2 = 224.3 cm-cGy/Gy, µ2 = −7.43 cm,
and σ2 = 10.28 cm from the previous study.
To replace the TPS-calculated values with those calculated by the model, we used the following
computational methods. The 50% isodose surface was converted to a contoured structure using the TPS.
Then the DICOM-RT objects for the dose distributions and contoured structures were exported from the
TPS to separate RT Dose and RT Structure Set formatted files, respectively. The coordinates and doses
of each voxel in the RT Dose file and the coordinates of each vertex of the 50% isodose surface in the RT
Structure Set file were read into an in-house code and processed using commercial software (MATLAB
R2008b, The MathWorks, Inc., Natick, MA, USA). For each voxel that was both outside the 50% isodose
surface and at a distance greater than 1 cm from the nearest vertex of the 50% isodose surface, the code
replaced Hv with the model-based estimate from Equation (5). The resulting position and dose data were
converted back into a DICOM RT Dose file, and HT values were calculated as described in Section 2.2.
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2.5. Risks of SMN Incidence and Mortality
The excess absolute lifetime risks of radiogenic cancer incidence, IT , and mortality, MT , were
estimated for specific cancer sites that correspond to T using linear-no-threshold models:




IT
MT
IT =
· HT and MT =
· HT
(6)
HT
HT
in which IT /HT and MT /HT were risk coefficients derived from the age-, sex-, and organ-specific risk
models of the BEIR VII Report of the National Research Council of The National Academies [43].
IT /HT and MT /HT coefficients for each T were interpolated linearly between values for a 10-year-old
girl and a 15-year-old girl from Tables 12D-1 and 12D-2 in the BEIR VII Report. H remainder was used
to estimate the risk of other solid cancers, and H redbonemarrow was used to estimate the risk of leukemia.
This risk model was used for all cancers with the following exceptions in which recommended risk
coefficients were not provided in the BEIR VII Report. For non-melanoma skin cancer (NMSC), we
applied values of I skin /H skin and M skin /H skin that we derived from ICRP Publication 60 [36], adjusting
for age and sex, as described previously [10]. For M thyroid /H thyroid , we multiplied the interpolated value
for I thyroid /H thyroid by the proposed lethality fraction for thyroid cancer of 0.1 from ICRP Publication 60.
Thus, we took into account all known radiogenic cancer risks.
The risk coefficients for all cancers except leukemia had been reduced by a dose and dose rate
effectiveness factor (DDREF) of 1.5 that corrected the risk models for low dose (<100 mGy) or low
dose rate (<0.01 mGy/min) exposures. Because the organ doses in this study were moderate to high, we
removed the DDREF by increasing IT /HT and MT /HT by a factor of 1.5 for all cancers except leukemia.
Similarly, we excluded DDREF for I skin /H skin and M skin /H skin . The final values of IT /HT and MT /HT ,
after adjustment for DDREF, for a 13-year-old girl are listed in Table 3.
Table 3. Risk coefficients for radiogenic cancer incidence, IT /HT , and mortality, MT /HT , for
a 13-year-old girl, listed in terms of absolute risk (in percent) per equivalent dose (in Sv).
Cancer Site

IT /HT (%/Sv)

MT /HT (%/Sv)

Stomach

0.98

0.55

Colon

2.15

1.00

Liver

0.26

0.23

Lung

6.78

5.96

Breast

9.25

2.17

Uterus

0.49

0.11

Ovary

0.98

0.54

Bladder

2.07

0.58

Thyroid

3.25

0.33

Leukemia

0.80

0.52

NMSC

17.77

0.04

Other solid

6.82

2.93

Risks are reported in percentages, meaning the number of SMNs or SMN fatalities per 100
13-year-old girls treated with these methods.
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3. Results
3.1.
Absorbed Dose, RBE-Weighted Absorbed Dose, and Equivalent Dose
3.1.Figure
Absorbed
Dose,
and Equivalent
Dose
1 shows
theRBE-Weighted
distributions ofAbsorbed
Dv of theDose,
therapeutic
fields as calculated
by the TPSs. In the axial
plane shown, the proton CSI plan had a narrower (left to right) but deeper 100% isodose line than the
Figure 1 shows the distributions of Dv of the therapeutic fields as calculated by the TPSs. In the axial
photon CSI plan. These effects resulted from differences in standards of care at the two clinics, with
plane shown, the proton CSI plan had a narrower (left to right) but deeper 100% isodose line than the photon
AUBMC having wider lateral margins for photon CSI and MD Anderson including the distal portion of
CSI plan. These effects resulted from differences in standards of care at the two clinics, with AUBMC
the vertebral body in the proton CSI target volume, both of which are to avoid a steep dose gradient in
having wider lateral margins for photon CSI and MD Anderson including the distal portion of the vertebral
the vertebrae for patients that are still maturing and subsequently to reduce the risk of asymmetric bone
body in the proton CSI target volume, both of which are to avoid a steep dose gradient in the vertebrae
growth
[24].that are still maturing and subsequently to reduce the risk of asymmetric bone growth [24].
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from the whole body volume, the organs and tissues receiving the highest HT in proton CSI were the red
bone marrow, remainder, skin, and lungs.
Table 4. Mean organ equivalent dose, HT , for proton CSI of a 13-year-old girl at MD
Anderson. The values in the table include HT attributable to therapeutic protons, neutrons
generated in the treatment unit (“external neutrons”), and neutrons generated in the patient
(“internal neutrons”). The TPS does not estimate statistical uncertainty in dose, and the
statistical uncertainties for neutron HT values were less than 3%.
HT (Sv)
Organ or Tissue

Primary Protons

External Neutrons

Internal Neutrons

Total

Stomach

0.01

0.34

0.14

0.49

Colon

0.08

0.27

0.11

0.46

Liver

0.39

0.38

0.12

0.89

Lungs

1.82

0.48

0.17

2.47

Breasts

0.00

0.32

0.07

0.39

Uterus

0.00

0.21

0.08

0.29

Ovaries

0.00

0.18

0.07

0.25

Bladder

0.00

0.13

0.06

0.19

Thyroid

0.45

0.44

0.31

1.20

Red bone marrow

4.41

0.24

0.14

4.79

Skin

2.40

0.27

0.12

2.79

Remainder

2.84

0.27

0.16

3.27

Whole body

2.52

0.27

0.15

2.94

Values of HT for photon CSI at AUBMC are listed in Table 5 for each of the three methods of
estimating out-of-field dose. In photon CSI, the uterus, ovaries, and bladder were entirely out-of-field,
and all other volumes were partially in-field. The sensitivity analysis (see Section 2.4.2) for each of
the partially in-field organs revealed that the TPS was sufficiently accurate for calculating HT values.
This was true even for the breast, in which only 12% of the volume was within the 5% isodose surface.
Therefore, in the volume-weighted average approach, HT was modified only for the uterus, ovaries, and
bladder, as shown in Table 5. The model-based approach for replacing the out-of-field dose resulted in
higher HT values. Those increases in HT were slight in the whole body, stomach, remainder, red bone
marrow, and skin (percent difference ≤10%); moderate in the colon, liver, and lungs (10% < percent
difference ≤ 50%), and large in the bladder, uterus, breasts, and ovaries (percent difference >50%).
Compared to the model-based approach, the TPS calculation underestimated H breasts by more than a
factor of 2. The volume-weighted approach resulted in higher H uterus , H ovaries , and H bladder values
that were higher than those of the TPS calculations but lower than those of the model-based approach.
Because it was entirely in-field, the choice of methods had no effect on the reported thyroid dose. The
organs and tissues receiving the highest HT in photon CSI at AUBMC were the thyroid, stomach, colon,
red bone marrow, and lungs.
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After accounting for out-of-field dose, HT values were higher for photon CSI at AUBMC than for
proton CSI at MD Anderson in all organs and tissues except the skin, which had approximately equal
HT . The red bone marrow, remainder, and whole body organs also had HT values for photon CSI that
were within a factor of 2 of those of proton CSI. Other radiosensitive organs and tissues had HT values
for photon CSI that were factors of 2.3 to 20.1 higher than those of proton CSI.
Table 5. Mean organ equivalent dose, HT , for photon CSI of a 13-year-old girl at
AUBMC. Three distinct methods were compared (see Section 2.4). The values from the
far right column were used in SMN risk assessments and comparisons with proton CSI at
MD Anderson.

Organ or
Tissue

TPS
Only

HT (Sv)
Volume-Weighted
Averaging Technique

Stomach

9.48

9.48

9.73

Colon

6.12

6.12

6.82

Liver

4.64

4.64

5.33

Lungs

4.78

4.78

5.59

Breasts

0.72

0.72

1.57

Uterus

0.02

0.60

1.11

Ovaries

0.02

0.60

1.70

Bladder

0.03

0.60

1.10

Thyroid
Red bone
marrow

16.75

16.75

16.75

5.49

5.49

5.88

Skin

2.58

2.58

2.80

Remainder

4.77

4.77

4.91

Whole body

4.53

4.53

4.64

TPS in-Field & Model
Out-of-Field

3.2. Risk of SMN Incidence and Mortality
IT values from photon CSI at AUBMC and proton CSI at MD Anderson are shown in Figure 2, as
are the ratios of IT for proton CSI to IT for photon CSI. The SMN with the highest IT values for photon
CSI were thyroid cancer, NMSC, lung cancer, and other solid cancers. Those with highest IT values for
proton CSI were NMSC, other solid cancers, and lung cancer. Differences in IT of 5% or more between
the two treatments were found for thyroid, lung, colon, breast, stomach, and other solid cancers; and
differences in IT for the other cancers were less than 2%. Ratios of IT were less than 1 for all cancers
except NMSC and were smallest for stomach, colon, and thyroid cancers. The ratio of the sums of IT
for all cancers was 0.46 when including NMSC and 0.30 when excluding NMSC. NMSC accounted
for one-quarter and one-half of the sums of IT in photon CSI and proton CSI, respectively. In photon
CSI, only one-tenth of the total risk of SMN incidence was from out-of-field dose, but in proton CSI,
one-quarter of the total risk of SMN incidence was from stray radiation.
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MT values from photon CSI at AUBMC or proton CSI at MD Anderson are shown in Figure 3 along
with the ratios of MT for proton CSI to MT for photon CSI. The SMN sites of greatest concern for a
radiation-related fatality were lung cancer and other solid cancers in both cases. The ratios of risk for
each SMN site were identical to those for incidence. Differences in MT of 5% or more were found for
lung, colon, stomach, thyroid, and other solid cancers. The ratio of risk of SMN mortality for all cancer
sites was 0.39, and the risk of fatality from NMSC was negligible. In photon CSI, one-eighth of the total
risk of SMN mortality was from out-of-field dose, and in proton CSI, one-quarter of the total risk of
SMNCancers
mortality
was7 attributable to stray radiation.
2015,
419
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4. Discussion
We performed an inter-institution comparison study on the predicted lifetime attributable risks of
SMN incidence and mortality for a 13-year-old girl receiving photon CSI at an academic cancer center in
the Middle East with those for the same patient receiving proton CSI at an academic cancer center in the
U.S., taking into account both primary and stray radiation and all known radiogenic cancers. We found
that the risks of incidence or mortality for proton CSI were approximately half those for photon CSI. With
proton CSI, the absolute risks of SMN incidence were especially reduced for thyroid, lung, colon, breast,
stomach, and other solid cancers compared to photon CSI. The specific SMN of greatest concern for a
radiation-related fatality was lung cancer, accounting for half the risk in each case. It was also lung cancer
for which proton therapy yielded the greatest reduction in absolute SMN mortality risk. Stray radiation
contributed to the incidence and mortality risks in both treatment modalities and was especially important
in proton CSI, even though the total risk remained lower in all cancer sites. This study demonstrated the
feasibility of comparative inter-institutional whole-body dose and risk assessment capabilities.
The predicted lifetime absolute attributable risks of SMN incidence and mortality in this study were
high. This was true even for SMNs that originate outside the craniospinal axis. In a previous study for a
4-year-old boy undergoing proton CSI or photon CSI at MD Anderson [19], we found that high predicted
risk of SMN incidence for the first 30 years after exposure were comparable to but lower than the
observed excess risk of SMN incidence in the exposed population of a large-scale epidemiological study
(Childhood Cancer Survivor Study) [44]. Like us, Meadows et al. found that the probability of NMSC
incidence was high. As time after exposure increases, the treatment-related incidence and mortality rates
for their cohort likely will increase. In a study involving 10 pediatric patients, Brodin et al. [15] also
predicted high excess absolute risks of SMN incidence (>40% over a lifetime) following photon CSI
and moderate excess risks of this outcome (<20% over a lifetime) following intensity-modulated proton
CSI. Therefore, the findings of Brodin et al. agree with our high predicted risk of SMN incidence our
patient and decreased risk of SMN incidence by using proton instead of photon CSI. In a previous study
for a cohort of 17 patients receiving proton CSI or photon CSI within MD Anderson, we found the
ratios of SMN risks from proton CSI versus photon CSI to range between 0.10 to 0.22 for incidence
and between 0.20 and 0.53 for mortality [16]. Our ratio for mortality in this study (0.39) fell within the
range of values of the previous study, but our ratio for incidence (0.46) did not. This difference is likely
due to our more comprehensive estimates of radiation carcinogenesis in this study that included NMSC,
leukemia, and other solid cancers. A direct comparison between SMN incidence and mortality due to
photon CSI at MD Anderson and photon CSI at AUBMC is not easily obtained because of the differing
methods between the two studies.
For the patient and treatment tested here, one-sixth of the risks of SMN incidence and mortality in
proton CSI were due to external neutrons. This finding confirms a similar previous result for a 3-year-old
boy [14]. By neglecting the equivalent dose from external neutrons, we can obtain a first approximation
for the decline in risks that may result from using to intensity-modulated proton therapy (IMPT). IMPT
is being used increasingly for pediatric radiotherapy [45]. Some existing and most new proton therapy
installations under construction are designed to deliver magnetically scanned proton beams capable of
IMPT. With these units, patients receive negligible external neutron exposures compared to therapeutic
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proton and internal neutron exposures. In previous study for a 3-year-old boy [14], we expanded the
methods of study into the reduction of lifetime SMN risk that may be achievable by proton therapy by
Miralbell et al. [17] to include contributions from secondary neutrons. In that study, passively-scattered
proton CSI reduced the risk of SMN incidence compared to conventional photon CSI by a factor of 10.7,
and scanned-beam proton CSI (a closer approximation to IMPT) was estimated to increase this factor
to 12.4. The possibility of a further reduction in SMN risk with the use of IMPT should be explored
more systematically.
We estimated the predicted risks of incidence of NMSC and found them to be approximately equal
between proton and photon CSI. NMSC is the most common treatment-related subsequent neoplasm
in childhood cancer survivors [44] and has been found in survivors as young as 7 years and as old
as 46 years, with 10% of the tumors appearing outside the treatment field among patients receiving
radiotherapy [46]. Of particular concern was a finding by Armstrong et al. [47] that NMSC is often
followed by other SMN. Among childhood cancer survivors who had received radiotherapy within the
previous 15 years and who had two or more SMN, the risk of multiple subsequent neoplasms was twice
as high for those whose first subsequent neoplasm was an NMSC than for those whose first subsequent
neoplasm was not. For these reasons, although NMSC is rarely fatal, it was important to estimate NMSC
risk for this study.
Children are particularly susceptible to SMN and some other late effects because of the radiation
sensitivity of their organs and tissues, the proximity of non-target organs and tissues to the treatment
fields, and the ongoing development of their organs [48–50]. Therefore, understanding the role of
advanced techniques to reduce radiotherapy-induced SMN risk is especially important for children.
Furthermore, childhood cancer survivors generally have a high likelihood of long-term survival. In
our study, we predicted that SMNs are avoidable by applying proton CSI rather than photon CSI. If
advanced techniques such as proton therapy are proven to be superior for reducing late effects in children
of all ages, countries in which proton therapy is not available may be inspired to devise creative means
of making these modalities available to their children, for example, by sending their pediatric patients
abroad for proton therapy [51]. However, then they must overcome a difficult obstacle, namely, that
arranging for proton therapy in another country can take weeks or even months, which is inconsistent
with the need to start irradiation within 30 days of surgery. Furthermore, we acknowledge that some
countries lack resources for oncology care in general, and providing proton CSI for children may be low
on their priority lists. Still, as the number of proton therapy clinics is growing rapidly, sending children
to a centralized proton radiotherapy clinic is becoming more plausible.
The main limitations of our study are associated with the risk models. The uncertainties in risk
are large and difficult to estimate, owing in part to the imprecise understanding of the applicability of
DDREF in fractionated radiotherapy. The risk model has other inherent limitations. The models were
derived from data from a general population, mainly atomic bomb survivors, and the application of these
risk models to cancer patients receiving therapeutic doses introduces uncertainty in the risk predictions
that is difficult to quantify [14,43,52,53]. Furthermore, the comprehensive SMN risk models used in this
study were intended to be applied to a population, not to individuals, and the mortality risk coefficients
were meant for health care in the United States. We acknowledge these systematic uncertainties and note
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that they limit our ability to predict risk with accuracy. However, our ratio-of-risk results and our general
findings are less affected by these uncertainties than our absolute risk values.
5. Conclusions
In summary, this case study demonstrated the feasibility of inter-institutional whole-body dose and
risk assessments and provided further evidence that proton radiotherapy reduces the risk of late effects for
children with brain cancer vs. photon therapy. Specifically, when considering all radiogenic cancers, we
found that a 13-year-old girl receiving proton CSI incurred much lower predicted risks of SMN incidence
and mortality than she would if receiving photon CSI. The SMN of greatest concern for mortality was
lung cancer. The results of our study suggest that the risk of radiogenic cancer may be reduced and
quality of life improved for children needing CSI in countries in which proton therapy is not available
if proton therapy is accessible to them; however, more research is needed to confirm these findings in
patients of various ages and both sexes.
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